Press releases

Mar 31

Investigational New Drug (IND)-enabling Studies for Sachi Bio's lead molecule

Sachi Bio's lead program NI112 shows excellent Safety-Toxicity, brain-delivery, and biodistribution profile in Investigational New Drug...

Jan 31

Sachi Bio lead programs to support NASA Missions & counter debilitating diseases on Earth

"Sachi Bio has successfully advanced it's lead program towards translation for a range of neurodegenerative diseases, as well as a...

Nov 30, 2023

Sachi Bio wins US National Academy of Medicine Sponsored "Healthy Longevity Global Challenge" for Healthy Aging

Starting in 2030, we will witness a historic milestone as the elderly population surpasses the youth for the first time ever. This...

Jul 31, 2023

Sachi Bio awarded SBIR Phase III contract from NASA for Rapid, Low-Cost Drug-Discovery in Space

Sachi Bio has been selected to provide potential scientific and commercialization evidence for use of accelerated aging and...

Mar 31, 2023

Sachi's NanoligomerTM platform can deliver to the brain with systemic administration

Brain delivery of Nanoligomer using systemic administration What if you could deliver RNA therapeutics to the brain for high-precision...

Ph: 720-361-2159

3000 Airport Drive, Unit 201,

Erie, CO 80516

Subscribe to Our Newsletter